Skip to main content

Table 2 Antiretroviral use and risk ratios for development of NHL in subjects after starting newer-class antiretroviral regimens

From: Early development of non-hodgkin lymphoma following initiation of newer class antiretroviral therapy among HIV-infected patients - implications for immune reconstitution

Antiretroviral

NHL cases (n = 5)

Controls (n = 73)

Unadjusted Odds Ratio

95% CI

Nucleos(t)ide reverse transcriptase inhibitors

100%

97%

NC

(p = 1.0)

Raltegravir

100%

86%

NC

(p = 1.0)

Etravirine

20%

53%

0.29

0.02-2.0

Maraviroc

0

11%

0

 

Darunavir/ritonavir

80%

59%

2.8

0.30-26.6

Enfuvirtide

20%

4%

5.8

0.40-69.5

  1. NC: not calculated